MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$3,587K
(58.44%↑ Y/Y)
Net loss
-$3,585K
(58.37%↑ Y/Y)
Total other
comprehensive gain
-$2K
(90.00%↑ Y/Y)
Loss from continuing
operations
-$3,585K
(58.33%↑ Y/Y)
Unrealized gaines on
marketable securities, net...
-$2K
(90.00%↑ Y/Y)
General and
administrative
$3,085K
(-5.80%↓ Y/Y)
Other segment items
$473K
(-53.90%↓ Y/Y)
Research and
development-Research And Development...
$194K
(-92.30%↓ Y/Y)
Research and
development-Repibresib VYN201
$150K
(-94.18%↓ Y/Y)
Loss from continuing
operations before income...
-$3,585K
(58.33%↑ Y/Y)
Other income, net
$231K
(-61.11%↓ Y/Y)
Total operating
expenses
$3,902K
(-58.48%↓ Y/Y)
Operating loss
-$3,816K
(58.51%↑ Y/Y)
Total revenues
$86K
(-57.43%↓ Y/Y)
Operating loss
-$3,816K
(58.51%↑ Y/Y)
Total operating
expenses
$3,902K
(-58.48%↓ Y/Y)
General and
administrative
$3,085K
(-5.80%↓ Y/Y)
Research and development
$817K
(-86.66%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)